Literature DB >> 6589233

High-performance liquid chromatographic determination of citalopram and four of its metabolites in plasma and urine samples from psychiatric patients.

E Oyehaug, E T Ostensen, B Salvesen.   

Abstract

A high-performance liquid chromatographic method is used for the determination of citalopram [1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-5-phthalancarbonitrile+ ++] and four of its metabolites (the methylamino, amino, propionic acid and N-oxide derivatives) in plasma and urine. The plasma samples were extracted with diethyl ether at pH 10 and pH 4. Filtered urine samples could be injected directly on to the column. Steady-state drug and metabolite levels were investigated in fifteen psychiatric patients. In urine, 12 +/- 5% (mean +/- S.D.) of a given dose of citalopram was excreted in unchanged form. The propionic acid derivative was further conjugated, possibly to glucuronic acid. Mean steady-state plasma levels and metabolites in 24-h urine are given as percentages of the dose.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6589233

Source DB:  PubMed          Journal:  J Chromatogr


  11 in total

1.  A validated spectrofluorimetric method for the determination of citalopram in bulk and pharmaceutical preparations based on the measurement of the silver nanoparticles-enhanced fluorescence of citalopram/terbium complexes.

Authors:  Muhammad Naeem Khan; Jasmin Shah; Muhammad Rasul Jan; Sang Hak Lee
Journal:  J Fluoresc       Date:  2012-09-27       Impact factor: 2.217

Review 2.  The clinical pharmacokinetics of escitalopram.

Authors:  Niranjan Rao
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 3.  Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors.

Authors:  P Baumann
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

4.  Citalopram and demethylcitalopram in human milk; distribution, excretion and effects in breast fed infants.

Authors:  J Rampono; J H Kristensen; L P Hackett; M Paech; R Kohan; K F Ilett
Journal:  Br J Clin Pharmacol       Date:  2000-09       Impact factor: 4.335

Review 5.  Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness.

Authors:  R J Milne; K L Goa
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

6.  The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4'-hydroxylase activity in human liver microsomes.

Authors:  K Kobayashi; T Yamamoto; K Chiba; M Tani; T Ishizaki; Y Kuroiwa
Journal:  Br J Clin Pharmacol       Date:  1995-11       Impact factor: 4.335

7.  Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes.

Authors:  Karin Herrlin; Norio Yasui-Furukori; Gunnel Tybring; Jolanta Widén; Lars L Gustafsson; Leif Bertilsson
Journal:  Br J Clin Pharmacol       Date:  2003-10       Impact factor: 4.335

8.  Changes in sleep polygraphic variables and clinical state in depressed patients during treatment with citalopram.

Authors:  A L van Bemmel; R H van den Hoofdakker; D G Beersma; A L Bouhuys
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 9.  Clinical pharmacokinetics of selective serotonin reuptake inhibitors.

Authors:  J van Harten
Journal:  Clin Pharmacokinet       Date:  1993-03       Impact factor: 6.447

10.  Spectrofluorimetric method for determination of citalopram in bulk and pharmaceutical dosage forms.

Authors:  S G Vasantharaju; S Lakshmana Prabu; A Jacob
Journal:  Indian J Pharm Sci       Date:  2008-09       Impact factor: 0.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.